Autolus Therapeutics plc - American Depositary Share (AUTL) News

Autolus Therapeutics plc - American Depositary Share (AUTL): $2.19

-0.05 (-2.23%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AUTL to Watchlist
Sign Up

Industry: Biotech


Ranked

of 388

in industry

Filter AUTL News Items

AUTL News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest AUTL News From Around the Web

Below are the latest news stories about AUTOLUS THERAPEUTICS PLC that investors may wish to consider to help them evaluate AUTL as an investment opportunity.

H.C. Wainwright Remains a Buy on Autolus Therapeutics (AUTL)

H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Autolus Therapeutics (AUTL - Research Report) today and set a price target of $11.00. The company's shares closed yesterday at $3.58.According to TipRanks, Burns is an analyst with an average return of -15.8% and a 30.08% success rate. Burns covers the Healthcare sector, focusing on stocks such as Portage Biotech Inc, Springworks Therapeutics, and BioNTech SE.Currently, the analyst consensus on Autolus Therapeutics is a Strong Buy with an average price target of $13.00, implying a 263.13% upside from current levels. In a report released on August 4, Mizuho Securities also maintained a Buy rating on the stock with a $18.

Jason Carr on TipRanks | August 18, 2022

Analysts Offer Insights on Healthcare Companies: RegenXBio (RGNX) and Autolus Therapeutics (AUTL)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on RegenXBio (RGNX – Research Report) and Autolus Therapeutics (AUTL – Research Report). RegenXBio (RGNX) Wedbush analyst Andreas Argyrides maintained a Hold rating on RegenXBio today and set a price target of $32.00. The company's shares closed last Thursday at $34.74. According to TipRanks.

Christine Brown on TipRanks | August 4, 2022

Autolus Therapeutics Reports Second Quarter 2022 Financial Results and Operational Progress

- Conference call to be held on August 4, 2022 at 8:30 am ET/1:30 pm BST -LONDON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its operational and financial results for the second quarter ended June 30, 2022. “Autolus has had a successful second quarter, with progress made across all fronts. We were awarded Regenerative Medicine Advanced Therapy (RMAT)

Yahoo | August 4, 2022

Correction - Autolus Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022

In the previous version the link to register for the conference call was incorrect – this press release contains the correct link to register for the call, and replaces the earlier version LONDON, July 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2022 financial results and operational highlights before open of U.S. mar

Yahoo | July 21, 2022

Autolus Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022

LONDON, July 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2022 financial results and operational highlights before open of U.S. markets on Thursday, August 4, 2022. Management will host a conference call and webcast at 8:30 am ET/1:30 pm BST to discuss the company’s financial results and provide a general business upda

Yahoo | July 21, 2022

Is Autolus Therapeutics (NASDAQ:AUTL) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | July 11, 2022

Autolus Therapeutics to Participate in William Blair’s Biotech Focus Conference 2022, New York, July 12 – 13, 2022

LONDON, July 06, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that management will be attending William Blair’s Biotech Focus Conference 2022 at The St. Regis New York in New York City. Autolus’ Chief Executive Officer, Dr. Christian Itin, will participate in a panel discussion on ‘Operationalizing Cell Therapies’ on Tuesday, July 12 at 8.55 – 10.15 am ET (1:55

Yahoo | July 6, 2022

Needham Thinks Autolus Therapeutics’ Stock is Going to Recover

In a report released today, Gil Blum from Needham maintained a Buy rating on Autolus Therapeutics (AUTL – Research Report), with a price target of $13.00. The company's shares closed last Monday at $2.28, close to its 52-week low of $2.20. According to TipRanks.com, Blum is ranked 0 out of 5 stars with an average return of -36.2% and a 18.6% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Rocket Pharmaceuticals, and Aeglea Biotherapeutics. Currently, the analyst consensus on Autolus Therapeutics is a Strong Buy with an average price target of $14.00, a 444.7% upside from current levels.

Catie Powers on TipRanks | June 14, 2022

Autolus Therapeutics (AUTL) Receives a Buy from Mizuho Securities

Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Autolus Therapeutics (AUTL – Research Report) today and set a price target of $18.00. The company's shares closed last Monday at $2.32, close to its 52-week low of $2.20. According to TipRanks.com, Goldstein is a 1-star analyst with an average return of -0.8% and a 33.4% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Neoleukin Therapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Autolus Therapeutics with a $14.00 average price target.

Howard Kim on TipRanks | June 13, 2022

Autolus Therapeutics Presents Clinical Data Updates at the European Hematology Association Congress

- AUTO4 shows high level of clinical activity with a novel targeting approach for patients with T Cell Lymphoma- AUTO1/22 demonstrates encouraging and durable responses in children ineligible for commercial CAR T product- Obe-cel shows high level of sustained clinical activity in B-NHL patients and first activity in Primary CNS Lymphoma Conference call to be held on Monday June 13, 2022 at 7:30 am EST/12:30 pm BST LONDON, June 10, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL),

Yahoo | June 10, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6131 seconds.